NCT00516451已完成1 期
Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- To determine the Maximum Tolerated Dose, the Dose Limiting Toxicity of BMS-690514
研究概览
简要总结
The purpose of this clinical study is to identify the maximum tolerated dose (MTD) of BMS-690514 once daily orally in Japanese subjects with advanced or metastatic solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate, with adequate kidney, liver and cardiac function.
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
干预措施: BMS-690514 (Drug)
结局指标
主要结局
To determine the Maximum Tolerated Dose, the Dose Limiting Toxicity of BMS-690514
时间窗: administered orally every day 28 days
次要结局
- Evaluate safety, exposure levels of BMS-690514 in the body & anticancer activity of BMS-690514 administered orally every day for 28 days.(throughout the study)
- Safety evaluations and laboratory assessments will be performed(throughout the study)
- Preliminary markers of efficacy will also be assessed(throughout the study)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOXCancerNCT00479583Bristol-Myers Squibb25
已完成
1 期
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid TumorsCancerTumorNCT00329004Bristol-Myers Squibb89
已完成
1 期
A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate CancerProstate CancerNCT00644488Bristol-Myers Squibb7
终止
1 期
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)Non Small Cell Lung CancerNCT00461110Bristol-Myers Squibb35
已完成
1 期
Study of Dasatinib (BMS-354825) in Patients With Solid TumorsTumorsNCT00339144Bristol-Myers Squibb16